Colox : une innovation «made in Switzerland»

Le cancer du côlon tue 5 personnes par jour en Suisse. « Une réalité inadmissible » s’insurge Brian Haschemi, chairman de Novigenix, start-up biotech située au coeur du Biopôle à Lausanne. Inadmissible car une détection précoce du cancer colorectal permet sa guérison. Aujourd’hui 2e cancer le plus meurtrier, l’éradication du cancer colorectal représente à la

De | 2017-11-22T12:37:58+00:00 15 novembre 2017|News Novigenix|

Le cancer du côlon

Le cancer du côlon représente la deuxième cause de mortalité par cancer chez les hommes et les femmes en Europe1. Le nombre de cas devrait encore augmenter ces vingt prochaines années en raison du vieillissement de la population. Mais s’il est diagnostiqué suffisamment tôt, le cancer du côlon a un taux élevé de guérison et

De | 2017-12-08T11:03:52+00:00 10 avril 2017|information médicale|

Novigenix Signs Distribution Agreement with Dr Risch Medical Laboratory to Access Swiss German Market for Colox®, its blood based colorectal cancer test

Agreement significantly increases access to Colox® in Switzerland and Liechtenstein LAUSANNE, Switzerland, March 15, 2017 – Novigenix SA today announced a commercialization agreement with Dr Risch Medical Laboratory for Colox, its blood test for the early detection of colorectal cancer (CRC). Dr Risch is a successful and science-driven clinical laboratory organization with a strong foothold

De | 2017-10-24T10:12:24+00:00 15 mars 2017|Communiqué de presse|

Novigenix publishes multi-center study of Colox® in Clinical Cancer Research

Data validate blood-based test’s ability to detect colorectal cancer early and reliably LAUSANNE, Switzerland, May 9, 2015 – Novigenix SA today announced the publication of a clinical validation study of Colox in the highly ranked journal Clinical Cancer Research. Colox is a blood test based on a 29-gene host immune response panel in combination with

De | 2017-09-28T18:01:29+00:00 9 mai 2016|Communiqué de presse|

Novigenix acquires blood-based molecular diagnostics test Colox® and prepares its further commercial rollout in Switzerland and Europe to improve the early detection of colorectal cancer

LAUSANNE, Switzerland, February 12, 2015 – Molecular diagnostics company Novigenix SA announced today it acquired Colox®, a new molecular blood test for the detection of colorectal cancer and pre-cancerous lesions (adenomatous polyps). Colox has been approved for sale in Europe, and has been launched commercially in Switzerland. Novigenix aims to increase the availability of Colox

De | 2017-09-28T18:04:27+00:00 12 février 2015|Communiqué de presse|